MoneyTalks: Canary Capital’s Paul Hart is bullish about the biotech sector – here’s why

Paul Hart was interviewed by Stockhead regarding the Biotech Sector.  Please see below the article published November 5th, 2021.

MoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and analysts are looking at right now.

Biotech is hot right now

Hart said that Canary Capital is currently very bullish about the biotech sector.

“There are many diseases where existing medicines have limited efficacy and many others where there are very limited or no treatment options at all – commonly referred to as an unmet need,” he said.

“At Canary we try to identify companies which are at the forefront of developing new or superior treatments for chronic diseases which take the lives of many people around the world each year.

“We look for companies which are developing new technology and treatments which have the potential to become new frontiers in medicine.

“There are three biotech companies which we at Canary believe have the potential to transform how many diseases and conditions are treated.”

Follow the link to the article.

Stockhead article


Contact Us